Real-world cost-effectiveness of branded versus generic amoxicillin–clavulanate in hospitalized children with pneumonia
Keywords:
effectiveness, economic consequences, generic drug, pediatrics, pneumoniaAbstract
Background and aim: Pharmacoeconomic evidence evaluating the cost–effectiveness of brand and generic drugs of the amoxicillin–clavulanic acid combination in the treatment of pediatric pneumonia has not been widely reported in Vietnam. This study aims to analyze the cost-effectiveness of generic and brand-name drugs of the amoxicillin and clavulanic acid combination in the treatment of pneumonia.
Methods: This retrospective observational study was conducted on pediatric inpatients with pneumonia receiving generic drugs (n = 1069) and brand-name drugs (n = 1061) of the amoxicillin–clavulanic acid combination in a specialized pediatric hospital in Vietnam, from January 2024 to December 2025.
Results: Multivariate analysis, after adjusting for age, sex, comorbidity burden, baseline severity proxy, emergency admission, and referral status, showed that the generic drug group was associated with a 6% higher adjusted cost compared to the brand-name drug group (cost ratio 1.06, 95% CI: 1.01–1.11; p = 0.019); there was no statistically significant difference in treatment success between the generic and brand-name groups (adjusted OR = 0.37; 95% CI: 0.13–1.06; p = 0.065). Cost-effectiveness analysis indicated that, when using brand-name drugs as the comparison strategy, generic use was associated with higher observed direct medical costs (ΔC = 333,669 VND) and a small difference in effectiveness (ΔE = −0.007). Probabilistic sensitivity analysis showed that patients receiving generic drugs had a 59.9% probability of being associated with higher costs and lower effectiveness under the observed conditions.
Conclusions: In this single-center retrospective dataset, generic use was associated with higher observed direct medical costs, while treatment outcomes did not differ significantly between the two drug groups. Due to the observational design, causal interpretation is limited. These findings suggest that the cost of medication alone may not fully reflect the direct healthcare costs of treating pneumonia in hospitalized pediatric patients.
References
1. GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1811–72. doi:10.1016/S0140-6736(25)01917-8
2. Tran KQ, Pham VH, Vo CM, Pham QM, Nguyen PM. Comparison of Real-time Polymerase Chain Reaction and Culture for Targeting Pathogens in Pediatric Severe Community-Acquired Pneumonia. Turk Arch Pediatr. 2024;59(4):383–89. doi:10.5152/TurkArchPediatr.2024.24005
3. Lu Y. Determinants of childhood pneumonia: a retrospective hospital-based analysis. Front Med (Lausanne). 2025;12:1709403. doi: 10.3389/fmed.2025.1709403
4. Phuong NTK, Hoang TT, Foster K, Roberts CL, Marais BJ. Exploring pneumonia risk factors in Vietnamese infants: a survey of new mothers. BMJ Paediatr Open. 2017;1(1):e000155. doi:10.1136/bmjpo-2017-000155
5. Pham HT, Nguyen TNT, Tran QA, Ngo TT. Prevalence and Associated Factors with Mixed Coinfections among under 5-Year-Old Children with Severe Viral Pneumonia in Vietnam. J Child Sci. 2020;10(01):e74–79. doi:10.1055/s-0040-1713623
6. Hoang VT, Dao TL, Minodier P, et al. Risk Factors for Severe Pneumonia According to WHO 2005 Criteria Definition Among Children <5 Years of Age in Thai Binh, Vietnam: A Case-Control Study. J Epidemiol Glob Health. 2019;9(4):274–80. doi:10.2991/jegh.k.191009.001
7. Mrazek MF. Pharmaceutical pricing in the developing world: issues of access to medicines. Expert Rev Pharmacoecon Outcomes Res. 2002;2(1):43–50. doi:10.1586/14737167.2.1.43
8. World Health Organization. Promoting the use of quality assured generic and biosimilar medicines: WHO guideline on country pharmaceutical pricing policies. A plain language summary. Geneva: World Health Organization; 2021.
9. Piovani D, Clavenna A, Cartabia M, et al. Comparing recurrent antibiotic prescriptions in children treated with a brand name or a generic formulation. Pharmacoepidemiol Drug Saf. 2015;24(2):121–8. doi:10.1002/pds.3654
10. Prime Minister of Vietnam. Decision No. 376/QĐ-TTg approving the Program for the Development of the Pharmaceutical Industry and Domestic Medicinal Materials Production to 2030, with a Vision to 2045. Hanoi: Prime Minister of Vietnam; 2021.
11. National Assembly of Vietnam. Law No. 44/2024/QH15 on amendments and supplements to several articles of the Law on Pharmacy. Hanoi: National Assembly of Vietnam; 2024.
12. Nguyen TTP, Vu HTT, Hoang AM, et al. Barriers to Compliance with National Guidelines Among Children Hospitalized with Community-Acquired Pneumonia in Vietnam and the Implications. Antibiotics (Basel). 2025;14(7):709. doi: 10.3390/antibiotics14070709
13. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12):e008915. doi: 10.1136/bmjopen-2015-008915.
14. Zhukova OV, Konyshkina TM, Kononova SV. Fishburne’s method and the classical method of pharmacoeconomic analysis in the evaluation of antibiotic treatment of acute and recurrent bronchitis in children. Int J Pharm Pharm Sci. 2015;7(11):185–90.
15. Agius D, Mamo J, Calleja N, Smith AF, Carbonaro F. Estimating the costs and quality of life impact of vision loss in the population aged 50-80 years in Malta: evidence from The Malta Eye Study. Front Public Health. 2025;13:1706208. doi:10.3389/fpubh.2025.1706208
16. Klungphet K, Sakthong P, Intalapaporn P. Effectiveness and Economic Outcomes of Generic and Brand-Name Imipenem/Cilastatin in Thai Patients with Hospital-Acquired Pneumonia. J Health Res. 2014;28(5):309–17.
17. Qian C, Chen Q, Lin W, et al. Incidence of community-acquired pneumonia among children under 5 years in Suzhou, China: a hospital-based cohort study. BMJ Open. 2024;14(1):e078489. doi:10.1136/bmjopen-2023-078489
18. de-Miguel-Díez J, López-de-Andrés A, Hernández-Barrera V, et al. Sex-differences in incidence of hospitalizations and in hospital mortality of community-acquired pneumonia among children in Spain: a population-based study. Eur J Pediatr. 2022;181(7):2705–13. doi:10.1007/s00431-022-04478-9
19. Kirchner M, Schüpke S, Kieser M. Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpoints. Pharm Stat. 2024;23(5):678-86. doi:10.1002/pst.2375.
20. Nguyen TA, Knight R, Mant A, et al. Inflated medicine prices in Vietnam: a qualitative study. Health Policy Plan. 2017;32(5):647–56. doi:10.1093/heapol/czw174
21. Bauer TT, Welte T, Ernen C, et al. Cost Analyses of Community-Acquired Pneumonia From the Hospital Perspective. Chest. 2005;128(4):2238–46. doi:10.1378/chest.128.4.2238
22. Raut M, Schein J, Mody S, Grant R, Benson C, Olson W. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25(9):2151–57. doi: 10.1185/03007990903102743
23. U.S. Food and Drug Administration. Impact Story: Overcoming Challenges to Evaluating Bioequivalence in Complex Drugs [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [cited 2026 Aug 27]. Available from: https://www.fda.gov/drugs/science-and-research-drugs/impact-story-overcoming-challenges-evaluating-bioequivalence-complex-drugs
24. Al-Jazairi AS, Al-Ghamdi MA, Al-Suhaibani LK, et al. The clinical and Practice Dilemma of Frequent Switching Among Generic Medications: Magnitude and Patient Safety Prospective. Hosp Pharm. 2023;58(5):476–83. doi:10.1177/00185787231151858
25. Ordóñez K, Feinstein MM, Reyes S, Hernández-Gómez C, Pallares C, Villegas MV. Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia. Braz J Infect Dis. 2019;23(4):237–45. doi:10.1016/j.bjid.2019.06.010
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Thi Ngoc Nuoi Nguyen, Van De Tran, Duc Long Tran, Duc Tri Nguyen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
